Isabella C. Glitza

14.2k total citations
46 papers, 953 citations indexed

About

Isabella C. Glitza is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Isabella C. Glitza has authored 46 papers receiving a total of 953 indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 13 papers in Molecular Biology. Recurrent topics in Isabella C. Glitza's work include Cancer Immunotherapy and Biomarkers (26 papers), Brain Metastases and Treatment (17 papers) and CAR-T cell therapy research (11 papers). Isabella C. Glitza is often cited by papers focused on Cancer Immunotherapy and Biomarkers (26 papers), Brain Metastases and Treatment (17 papers) and CAR-T cell therapy research (11 papers). Isabella C. Glitza collaborates with scholars based in United States, Australia and China. Isabella C. Glitza's co-authors include Sriram Yennu, Éduardo Bruera, David Hui, Gary B. Chisholm, Michael A. Davies, Hussein A. Tawbi, Rodabe N. Amaria, Michael T. Tetzlaff, Adi Diab and Sapna P. Patel and has published in prestigious journals such as SHILAP Revista de lepidopterología, Cancer and Cancer Research.

In The Last Decade

Isabella C. Glitza

44 papers receiving 936 citations

Peers

Countries citing papers authored by Isabella C. Glitza

Since Specialization

Citations

This map shows the geographic impact of Isabella C. Glitza's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Isabella C. Glitza with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Isabella C. Glitza more than expected).

Fields of papers citing papers by Isabella C. Glitza

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Isabella C. Glitza. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Isabella C. Glitza. The network helps show where Isabella C. Glitza may publish in the future.

Co-authorship network of co-authors of Isabella C. Glitza

This figure shows the co-authorship network connecting the top 25 collaborators of Isabella C. Glitza. A scholar is included among the top collaborators of Isabella C. Glitza based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Isabella C. Glitza. Isabella C. Glitza is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanoma 2025 ·OncoImmunology ·(unknown), Simin Kiany, Marie‐Andrée Forget, Roland L. Bassett, Michael A. Davies, Adi Diab, Jeffrey E. Gershenwald, Isabella C. Glitza, Jeffrey E. Lee, Anthony Lucci, Jennifer L. McQuade, Sapna P. Patel, Merrick I. Ross, Hussein A. Tawbi, Jennifer A. Wargo, Michael K. Wong, Chantale Bernatchez, Patrick Hwu, Cara Haymaker, Rodabe Navroze Amaria	0
2	Hypofractionated Radiation Therapy for Unresectable or Bulky Metastatic Melanoma 2024 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), David Swanson, Ahsan Farooqi, (unknown), (unknown), (unknown), Isabella C. Glitza, (unknown), Russell S. Weiser, Sarah B. Fisher, Merrick I. Ross, (unknown), Devarati Mitra	0
3	1082O Concurrent intrathecal (IT) and intravenous (IV) nivolumab (N) for melanoma (MM) patients (pts) with leptomeningeal disease (LMD) 2023 ·Annals of Oncology ·Isabella C. Glitza, S. Phillips, (unknown), Roland L. Bassett, Ruitao Lin, Michelle Rohlfs, Jessie Richard, (unknown), (unknown), Ian E. McCutcheon, Sherise D. Ferguson, (unknown), Sudhakar Tummala, Nandita Guha‐Thakurta, (unknown), Hussein Tawbi, Elizabeth M. Burton, Michael A. Davies	2
4	1134P Safety and efficacy of low dose (LD) ipilimumab (Ipi) + pembrolizumab (pem) in checkpoint inhibitor (CPI) naïve patients (pts) with melanoma brain metastases (MBM) 2023 ·Annals of Oncology ·Isabella C. Glitza, Denái R. Milton, (unknown), Simon Turner, (unknown), Thomas H. Beckham, Rodabe N. Amaria, Sapna P. Patel, Adi Diab, Michael K. Wong, Jennifer L. McQuade, Cassian Yee, Michael A. Davies, Elizabeth M. Burton, Hussein A. Tawbi	4
5	1085O Atezolizumab, bevacizumab, and cobimetinib (TACo) in patients (pts) with PD1 refractory melanoma brain metastases (MBM) 2023 ·Annals of Oncology ·Elizabeth M. Burton, (unknown), Denái R. Milton, Isabella C. Glitza, (unknown), Sapna P. Patel, Adi Diab, Michael K. Wong, Jennifer L. McQuade, Caroline Chung, Jeffrey S. Wefel, J. Li, Michael A. Davies, Hussein A. Tawbi	1
6	Interstitial granulomatous dermatitis and concurrent immunotherapy associated encephalitis with nivolumab and ipilimumab 2022 ·Dermatology Online Journal ·(unknown), (unknown), (unknown), Jennifer L. McQuade, Isabella C. Glitza, Carlos A. Torres‐Cabala, (unknown)	1
7	1085P Ph I/II study of PI3K-β inhibitor GSK2636771 (G771) in combination with pembrolizumab (P) in patients (pts) with PTEN loss and melanoma or other advanced solid tumors 2021 ·Annals of Oncology ·Elizabeth M. Burton, Ecaterina E. Dumbrava, Weiyi Peng, Denái R. Milton, Rodabe N. Amaria, Jennifer L. McQuade, Isabella C. Glitza, David S. Hong, Sapna P. Patel, Jordi Rodón, (unknown), Aung Naing, Sarina A. Piha‐Paul, Gener Balmes, Alexander J. Lazar, Funda Meric‐Bernstam, Patrick Hwu, Michael A. Davies, Hussein A. Tawbi	3
8	The efficacy of anti‐programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma 2021 ·Cancer Medicine ·Dai Ogata, Lauren E. Haydu, Isabella C. Glitza, Sapna P. Patel, Hussein A. Tawbi, Jennifer L. McQuade, Adi Diab, Sühendan Ekmekçioglu, Michael K. Wong, Michael A. Davies, Rodabe N. Amaria	18
9	Circulating Tumor Cells and Early Relapse in Node-positive Melanoma 2020 ·Clinical Cancer Research ·Anthony Lucci, Carolyn Hall, Sapna P. Patel, (unknown), Jessica B. Bauldry, Richard E. Royal, Mandar Karhade, (unknown), Jennifer A. Wargo, Isabella C. Glitza, Michael K. Wong, Rodabe N. Amaria, Hussein A. Tawbi, Adi Diab, Michael A. Davies, Jeffrey E. Gershenwald, Jeffrey E. Lee, Patrick Hwu, Merrick I. Ross	52
10	1124P Phase Ib study to evaluate the safety of selinexor (SEL) in combination with pembrolizumab (PEM) in patients with advanced malignancies- the: The melanoma experience 2020 ·Annals of Oncology ·Isabella C. Glitza, Sapna P. Patel, Abdulrazzak Zarifa, Cheuk Hong Leung, Heather Lin, (unknown), Jing Gong, Bülent Yılmaz, Jenny Chambers, (unknown), (unknown), (unknown), Siqing Fu, Apostolia M. Tsimberidou, Filip Jankú, Daniel D. Karp, Funda Meric‐Bernstam, Aung Naing	3
11	Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions 2020 ·Pigment Cell & Melanoma Research ·Isabella C. Glitza, Keiran S.M. Smalley, Priscilla K. Brastianos, Michael A. Davies, Ian E. McCutcheon, James K. Liu, Kamran A. Ahmed, John A. Arrington, Brittany Evernden, Inna Smalley, Zeynep Eroglu, Nikhil I. Khushalani, Kim Margolin, Harriet M. Kluger, Michael B. Atkins, Hussein A. Tawbi, Adrienne Boire, Peter Forsyth	28
12	RADT-13. EARLY CONCURRENT IMMUNOTHERAPY WITH STEREOTACTIC RADIOSURGERY IS ASSOCIATED WITH PROLONGED SURVIVAL AND DECREASED DISTANT BRAIN FAILURE IN PATIENTS WITH NEWLY DIAGNOSED MELANOMA BRAIN METASTASES (MBM) 2020 ·Neuro-Oncology ·Alexander Augustyn, Roshal R. Patel, Ethan B. Ludmir, Lauren E. Haydu, Nandita Guha‐Thakurta, Andrew J. Bishop, Caroline Chung, Amol J. Ghia, Mary Frances McAleer, Susan L. McGovern, Chenyang Wang, Kristina D. Woodhouse, D.N. Yeboa, Sherise D. Ferguson, Betty Y.S. Kim, Isabella C. Glitza, Jing Li	1
13	Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD) 2019 ·Journal of Neuro-Oncology ·Sherise D. Ferguson, (unknown), Roland L. Bassett, Lauren E. Haydu, Ian E. McCutcheon, Amy B. Heimberger, Jing Li, Barbara O’Brien, Nandita Guha‐Thakurta, Michael T. Tetzlaff, Hussein A. Tawbi, Michael A. Davies, Isabella C. Glitza	42
14	Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2 2018 ·ESMO Open ·Isabella C. Glitza, Michelle Rohlfs, Nandita Guha‐Thakurta, Roland L. Bassett, Chantale Bernatchez, Adi Diab, Scott E. Woodman, Cassian Yee, Rodabe N. Amaria, Sapna P. Patel, Hussein A. Tawbi, Michael K. Wong, Wen-Jen Hwu, Patrick Hwu, Amy B. Heimberger, Ian E. McCutcheon, Nikolaos G. Papadopoulos, Michael A. Davies	47
15	A Phase 1/2 trial of intratumoral (i.t.) IMO-2125 (IMO) in combination with checkpoint inhibitors (CPI) in PD-(L)1-refractory melanoma 2017 ·Annals of Oncology ·Adi Diab, Cara Haymaker, Marc Uemura, Rashmi K. Murthy, (unknown), James Geib, Mark Cornfeld, S. Swann, Cassian Yee, Jennifer A. Wargo, (unknown), (unknown), Hussein A. Tawbi, Isabella C. Glitza, Scott E. Woodman, Wen‐Jen Hwu, Michael A. Davies, Willem W. Overwijk, Chantale Bernatchez, Patrick Hwu	11
16	Phase I Dose-Escalation Study of Anti–CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers 2017 ·Molecular Cancer Therapeutics ·Divya Sakamuri, Isabella C. Glitza, Sonia L. Betancourt Cuellar, Vivek Subbiah, Siqing Fu, Apostolia M. Tsimberidou, Jennifer J. Wheler, David S. Hong, Aung Naing, Gerald S. Falchook, Michelle A. Fanale, Maria E. Cabanillas, Filip Jankú	34
17	Abstract 246: Phase 1 study: Ipilimumab (anti CTLA-4) in combination with Lenalidomide in patients with advanced cancers 2015 ·Cancer Research ·Divya Sakamuri, Sonia L. Betancourt Cuellar, Isabella C. Glitza, Siqing Fu, Jennifer J. Wheler, Gerald S. Falchook, Apostolia M. Tsimberidou, David S. Hong, Vivek Subbiah, Michelle A. Fanale, Maria E. Cabanillas, Funda Meric‐Bernstam, Filip Jankú	1
18	517 Long-term efficacy of intrathecal interleukin-2 (IT IL2) in metastatic melanoma (MM) patients (pts) with leptomeningeal disease (LMD) 2015 ·European Journal of Cancer ·Isabella C. Glitza, Michelle Rohlfs, (unknown), (unknown), Jessie Richard, (unknown), (unknown), (unknown), (unknown), Adi Diab, Rodabe N. Amaria, Scott E. Woodman, (unknown), Cassian Yee, (unknown), Patrick Hwu, Nikolaos G. Papadopoulos, M. A. Davies	1
19	Attrition rates, reasons, and predictive factors in supportive care and palliative oncology clinical trials 2012 ·Cancer ·David Hui, Isabella C. Glitza, Gary B. Chisholm, Sriram Yennu, Éduardo Bruera	174
20	Longitudinal study of meningococcal carrier rates in teenagers 2007 ·International Journal of Hygiene and Environmental Health ·Isabella C. Glitza, Ingrid Ehrhard, Berit Müller‐Pebody, Ralf Reintjes, Thomas Breuer, A Ammon, H.‐G. Sonntag	27

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact